Immunotoxicity of pharmaceuticals: Current knowledge, testing strategies, risk evaluation & consequences for human health

被引：0

作者：

Van Der Laan J.W. ^{[1
]}

Van Loveren H. ^{[2
]}

Vos J.G. ^{[2
]}

Dean J.H. ^{[3
]}

Hastings K.L. ^{[4
]}

机构：

[1] Preclinical Assessment Group, Medicines Evaluation Board of the Netherlands, Laboratory for Medicines and Medical Devices, National Institute of Public Health and the Environment, NL-3720 BA Bilthoven

[2] Laboratory for Pathology and Immunobiology, National Institute for Public Health and the Environment, Bilthoven

[3] Sanofi Research, Sanofi Pharmaceuticals, Inc., Malvern, Pennsylvania

[4] Division of Antiviral Drug Products, Office of Drug Evaluation II, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland

来源：

Drug information journal : DIJ / Drug Information Association | 1997年 / 31卷 / 4期

关键词：

Allergenicity; Autoimmunity; Immunotoxicity; Pharmaceuticals;

D O I：

10.1177/009286159703100429

中图分类号：

学科分类号：

摘要：

This paper provides an overview of the DIA workshop on immunotoxicity of pharmaceuticals held on October 2-4, 1996, in Montreux, Switzerland. The importance of immunotoxicity testing, and its current status, are discussed. The workshop's agenda: current animal tests and clinical efforts for which preclinical immunotoxicity assays need to be developed, are highlighted. Conclusions from the meeting are provided. © 1997, Drug Information Association. All rights reserved.

引用

页码：1301 / 1305

页数：4

共 50 条

[1] Developmental immunotoxicity (DIT) testing of pharmaceuticals: Current practices, state of the science, knowledge gaps, and recommendations
Collinge, Mark
Burns-Naas, Leigh Ann
Chellman, Gary J.
Kawabata, Thomas T.
Komocsar, Wendy J.
Piccotti, Joseph R.
Shenton, Jacintha
Wierda, Daniel
[J]. JOURNAL OF IMMUNOTOXICOLOGY, 2012, 9 (02) : 210 - 230
[2] Current state of developmental immunotoxicity testing & knowledge gaps
Nygaard, U. C.
[J]. TOXICOLOGY LETTERS, 2022, 368 : S29 - S30
[3] Current Threat of Nitrosamines in Pharmaceuticals and Scientific Strategies for Risk Mitigation
Tuesuwan, Bodin
Vongsutilers, Vorasit
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (05) : 1192 - 1209
[4] Evaluation of Current Risk Evaluation and Mitigation Strategies
Gilsenan, Alicia
Andrews, Elizabeth B.
Calingaert, Brian
Crozier, Debra
Vanderpuije, Abenah
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S177 - S178
[5] A human health risk assessment of pharmaceuticals in the aquatic environment
Schulman, LJ
Sargent, EV
Naumann, BD
Faria, EC
Dolan, DG
Wargo, JP
[J]. HUMAN AND ECOLOGICAL RISK ASSESSMENT, 2002, 8 (04): : 657 - 680
[6] Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals
Van Deun, K
Van Cauteren, H
Vandenberghe, J
Canning, M
Vanparys, P
Coussement, W
[J]. ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS, 1997, 16 (04) : 215 - 233
[7] Human pharmaceuticals in US surface waters: A human health risk assessment
Schwab, BW
Hayes, EP
Fiori, JM
Mastrocco, FJ
Roden, NM
Cragin, D
Meyerhoff, RD
D'Aco, VJ
Anderson, PD
[J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2005, 42 (03) : 296 - 312
[8] Retrospective evaluation of the impact of functional immunotoxicity testing on pesticide hazard identification and risk assessment
Gehen, Sean C.
Blacker, Ann M.
Boverhof, Darrell R.
Hanley, Thomas R., Jr.
Hastings, Charles E.
Ladics, Gregory S.
Lu, Haitian
O' Neal, Fredrick O.
[J]. CRITICAL REVIEWS IN TOXICOLOGY, 2014, 44 (05) : 407 - 419
[9] Approaches to Develop Alternative Testing Strategies to Inform Human Health Risk Assessment of Nanomaterials
Stone, Vicki
Johnston, Helinor J.
Balharry, Dominique
Gernand, Jeremy M.
Gulumian, Mary
[J]. RISK ANALYSIS, 2016, 36 (08) : 1538 - 1550
[10] Human health risk assessment of pharmaceuticals in the European Vecht River
Duarte, Daniel J.
Oldenkamp, Rik
Ragas, Ad M. J.
[J]. INTEGRATED ENVIRONMENTAL ASSESSMENT AND MANAGEMENT, 2022, 18 (06) : 1639 - 1654

← 1 2 3 4 5 →